Innate Pharma (IPHA) Accounts Payables (2017 - 2025)
Innate Pharma's (IPHA) quarterly Accounts Payables came in at $17.5 million in Q4 2025, up 2.37% YoY from $17.1 million in Q4 2024, and up 28.46% on a QoQ basis from $13.6 million in Q2 2025.
Innate Pharma (IPHA) Accounts Payables (2017 - 2025) Analysis & Trends
Innate Pharma (IPHA) has 9 years of Accounts Payables data on file, last reported at $17.5 million in Q4 2025.
- Quarterly Accounts Payables rose 2.37% year-over-year to $17.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $17.5 million (up 2.37% YoY) and the FY2025 annual result came in at $17.5 million, up 2.37% from the prior year.
- Accounts Payables climbed to $17.5 million in Q4 2025, from $13.6 million in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $32.7 million in Q4 2021 to a low of $13.6 million in Q2 2025.
- A 5-year average of $19.9 million and a median of $19.1 million in 2022 frame the typical range for Accounts Payables.
- Annual changes were most pronounced in 2021 — Accounts Payables plunged 99.92% — and 2023, when it climbed 3.82%.
- Tracing IPHA's Accounts Payables over 5 years: stood at $32.7 million in 2021, then tumbled by 34.73% to $21.3 million in 2022, then dropped by 14.17% to $18.3 million in 2023, then fell by 6.58% to $17.1 million in 2024, then climbed by 2.37% to $17.5 million in 2025.
- The last three Accounts Payables figures came in at $17.5 million (Q4 2025), $13.6 million (Q2 2025), and $17.1 million (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Innate Pharma | 202.03 Mn | 202.03 Mn | - | 17.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 17.51 Mn |
| Jun 30, 2025 | 13.63 Mn |
| Dec 31, 2024 | 17.11 Mn |
| Jun 30, 2024 | 17.09 Mn |
| Dec 31, 2023 | 18.31 Mn |
| Jun 30, 2023 | 20.68 Mn |
| Dec 31, 2022 | 21.33 Mn |
| Jun 30, 2022 | 19.92 Mn |
| Dec 31, 2021 | 32.69 Mn |
| Jun 30, 2021 | 20.50 Mn |
| Dec 31, 2020 | 35.22 Mn |
| Jun 30, 2020 | 26.54 Bn |
| Dec 31, 2019 | 54.80 Mn |
| Dec 31, 2018 | 104.61 Mn |
| Dec 31, 2017 | 29.03 Mn |